Zanubrutinib Plus Rituximab for Patients With Indolent Mantle Cell Lymphoma
Condition(s):Mantle Cell LymphomaLast Updated:October 13, 2023Not yet recruiting
Hide Studies Not Open or Pending
Condition(s):Mantle Cell LymphomaLast Updated:October 13, 2023Not yet recruiting
Condition(s):Mantle Cell LymphomaLast Updated:March 22, 2024Not yet recruiting
Condition(s):Mantle Cell Lymphoma; Mantle Cell Lymphoma RefractoryLast Updated:January 8, 2024Recruiting
Condition(s):Mantle Cell LymphomaLast Updated:November 11, 2021Unknown status
Condition(s):Mantle Cell LymphomaLast Updated:November 1, 2022Not yet recruiting
Condition(s):Mantle Cell LymphomaLast Updated:February 20, 2024Recruiting
Condition(s):Mantle Cell Lymphoma (MCL)Last Updated:March 6, 2024Recruiting
Condition(s):Mantle Cell LymphomaLast Updated:July 5, 2023Recruiting
Condition(s):Mantle Cell LymphomaLast Updated:October 22, 2020Completed
Condition(s):Mantle Cell LymphomaLast Updated:December 14, 2023Active, not recruiting
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.